Oncology nurses and APPs play a key role in educating patients on BREAKWATER study findings and their impact on BRAF-mutant CRC treatment.
We came across a bullish thesis on Day One Biopharmaceuticals, Inc. (DAWN) on Twitter by Pharmdca. In this article, we will ...
The presence of primary resistance and KRAS G12C co-mutations may explain limited single-agent efficacy of marketed KRAS inhibitors, a recent study suggests.
Researchers at the University of California San Diego have uncovered a key mechanism underlying the treatment resistance of ...
HealthDay on MSN3d
Ultra-Rapid Molecular-Genetic Assays Feasible for Tumor Classification During SurgeryIntraoperative ultra-rapid droplet digital polymerase chain reaction (UR-ddPCR) can identify tumor genetic subtype and ...
Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C inhibitors, ...
Dywed Heddlu'r Gogledd fod nifer y galwadau a wnaed i dimau achub mynydd dros y ddau benwythnos diwethaf wedi bod "bron yn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback